Blood pressure medication made by Lupin Pharmaceuticals Inc. is being recalled by the U.S. Food and Drug Administration (FDA) for possibly containing a cancer-causing impurity. The voluntary recall includes the firm’s Irbesartan tablets and Hydrochlorothiazide tablets at the consumer level, according to the FDA. The FDA, in a news release last week, said that a “probable human carcinogen” was discovered after results from testing. “As part of Lupin’s ongoing assessment, analysis revealed that certain tested API batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan,” said the agency. Lupin hasn’t received any reports of illness that appear to be connected to the problem, said the FDA. But the firm, operating “out of an abundance of caution,” is now recalling all batches of Irbesartan Tablets in 75 mg, 150 mg, and 300 mg strengths; and Irbesartan and Hydrochlorothiazide Tablets USP in 150 mg/12.5 mg and 300 mg/12.5mg strengths in …